Review article: the use of potentially hepatotoxic drugs in patients with liver disease

被引:55
作者
Gupta, N. K. [1 ]
Lewis, J. H. [1 ]
机构
[1] Georgetown Univ, Med Ctr, Div Gastroenterol, Washington, DC 20007 USA
关键词
D O I
10.1111/j.1365-2036.2008.03822.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Misconceptions surround the use of hepatotoxic drugs in chronic liver disease. While many prescription and over-the-counter (OTC) agents can be used safely, this often runs counter to labelled warnings/contraindications, especially for the statins and other commonly used agents. Aim To evaluate published data on the use of hepatotoxic drugs in chronic liver disease including pharmacokinetic changes in cirrhosis and drug interactions, where available, to formulate recommendations on their use. Methods Using a combination of PubMed searches, review texts, the Physicians' Desk Reference and expert opinion, drugs considered at higher risk of hepatotoxicity in chronic liver disease were evaluated. Results Most drugs and OTC products including herbals have not been formally studied in chronic liver disease, but available data suggest that several of the most commonly used agents, especially the statins, can be used safely. While there is an increased risk of drug-induced liver injury for drugs used in the treatment of tuberculosis and HIV patients with hepatitis B or C, recommendations for their safe use are emerging. Conclusions Although many clinicians remain hesitant to use hepatotoxic drugs in chronic liver disease, the database supporting this view is limited to just a few agents. Most medications can be used safely in patients with chronic liver disease with appropriate monitoring.
引用
收藏
页码:1021 / 1041
页数:21
相关论文
共 190 条
[11]   Are recommended doses of acetaminophen hepatotoxic for recently abstinent alcoholics? A randomized trial [J].
Bartels, Susan ;
Sivilotti, Marco ;
Crosby, Deborah ;
Richard, Julie .
CLINICAL TOXICOLOGY, 2008, 46 (03) :243-249
[12]   A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J].
Belfort, Renata ;
Harrison, Stephen A. ;
Brown, Kenneth ;
Darland, Celia ;
Finch, Joan ;
Hardies, Jean ;
Balas, Bogdan ;
Gastaldelli, Amalia ;
Tio, Fermin ;
Pulcini, Joseph ;
Berria, Rachele ;
Ma, Jennie Z. ;
Dwivedi, Sunil ;
Havranek, Russell ;
Fincke, Chris ;
DeFronzo, Ralph ;
Bannayan, George A. ;
Schenker, Steven ;
Cusi, Kenneth .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2297-2307
[13]   ACETAMINOPHEN IN CHRONIC LIVER-DISEASE [J].
BENSON, GD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (01) :95-101
[14]  
*BOEHR ING PHARM, 2007, TIPR APT PACK INS
[15]   Statins and hepatic steatosis: Perspectives from the Dallas Heart Study [J].
Browning, Jeffrey D. .
HEPATOLOGY, 2006, 44 (02) :466-471
[16]   Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases [J].
Bruce, Robert D. ;
Altice, Frederick L. .
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2007, 33 (06) :869-874
[17]   Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure [J].
Brusco, F ;
González, G ;
Soto, N ;
Arteaga, E .
THYROID, 2004, 14 (10) :862-865
[18]   The human bile salt export pump: Characterization of substrate specificity and identification of inhibitors [J].
Byrne, JA ;
Strautnieks, SS ;
Mieli-Vergani, G ;
Higgins, CF ;
Linton, KJ ;
Thompson, RJ .
GASTROENTEROLOGY, 2002, 123 (05) :1649-1658
[19]  
Caldwell SH, 2001, AM J GASTROENTEROL, V96, P519
[20]   The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in Hunan nonalcoholic steatohepatitis [J].
Caldwell, Stephen H. ;
Patrie, James T. ;
Brunt, Elizabeth M. ;
Redick, Jan A. ;
Davis, Christine A. ;
Park, Sang H. ;
Neuschwander-Tetri, Brent A. .
HEPATOLOGY, 2007, 46 (04) :1101-1107